Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-acetylcysteine + saline is a combination formulation used primarily for inhalation therapy, where N-acetylcysteine (NAC) is diluted with normal saline before administration via nebulizer. N-acetylcysteine acts as a mucolytic agent by breaking disulfide bonds in mucus, thereby reducing its viscosity and facilitating airway clearance in conditions such as asthma, chronic bronchitis, cystic fibrosis, and other respiratory diseases characterized by thick or abnormal mucus secretions. Saline serves as the diluent to achieve the appropriate concentration for nebulization and to aid in humidification of airways. NAC also has antioxidant properties due to its role as a precursor to glutathione synthesis. The combination is not marketed under a unique brand name but is prepared extemporaneously for clinical use[4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-acetylcysteine + saline (Apothecon Pharmaceuticals).